(Q48606447)

13 February 2018

title

Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA. (English)

1 reference

13 February 2018

6

D B Calne

1 reference

13 February 2018

D J Doudet

1

1 reference

13 February 2018

G L Chan

2

1 reference

13 February 2018

J E Holden

3

1 reference

13 February 2018

B D Pate

4

1 reference

13 February 2018

K S Morrison

5

1 reference

13 February 2018

T J Ruth

7

1 reference

13 February 2018

language of work or name

English

0 references

publication date

1 September 1997

1 reference

13 February 2018

European Journal of Pharmacology

published in

1 reference

13 February 2018

volume

334

1 reference

13 February 2018

issue

1

1 reference

13 February 2018

page(s)

31-38

1 reference

13 February 2018

Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Routine determination of [18F]-L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Distribution and kinetics of 3-O-methyl-6-[18F]fluoro-L-dopa in the rhesus monkey brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

18F‐6‐Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR‐462)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Nigrostriatal function in humans studied with positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Pharmacological and clinical implications of MAO-B inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

Deprenyl: protective vs. symptomatic effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Selegiline as a primary treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2897%2901157-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(97)01157-6

1 reference

13 February 2018

1 reference

13 February 2018